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Background and objectives: Most patients with hypertension need ≥2 drugs to achieve goal 
blood pressure. This systematic review assessed efficacy and safety of triple vs. dual 
combination therapy for the management of hypertension. 
Methods: Publication databases, clinical trials registries and regulatory agency websites were 
searched until April 2018 for double-blind randomised controlled trials (RCTs) comparing 
triple with dual therapy of BP lowering drugs, for ≥3 weeks, among patients with 
hypertension. Meta-analyses for efficacy and safety outcomes were performed using 
random-effects model. Regimen efficacy was predicted using the Therapeutic Intensity Score 
(TIS) and the Law et al. method (which predict dose doubling increases efficacy by 100% and 
around 20%, respectively), and compared with observed efficacy.  
Results: Fourteen RCTs (11,457 participants) were included. Overall, triple compared to dual 
therapy reduced BP by 5.4/3.2 mmHg (P<0.001), and improved BP control by 58% vs. 45%, 
(relative risk (RR) 1.33 [95% CI 1.25-1.41]), while incidence of withdrawals due to adverse 
events (AEs) were 3.3% vs. 3.4% (RR 1.24 [95% CI 1.00-1.54], p=0.05). Law et al. method was 
superior to TIS in predicting differences in efficacy between triple and dual therapies. For 
patients uncontrolled on sub-maximal dose dual therapy, adding a third drug achieved on 
average approximately four times more BP reduction than doubling the dose of dual therapy 
component drugs (6.0/3.7 vs. 1.5/0.8 mmHg, respectively).  
Conclusion: Addition of a third drug is likely to be more efficacious without increasing AEs, 
compared to increasing dose of existing dual therapy. Early use of triple therapy can 
significantly improve hypertension control.  





Most people with hypertension require two or more blood pressure (BP) lowering drugs to 
achieve BP control under 140 mmHg systolic BP (SBP) [1, 2]. However, only about 30% of 
people treated for hypertension receive such therapy [3]. Recent evidence from randomised 
controlled trials (RCTs) has confirmed that further BP lowering within the 120-140 mmHg SBP 
range for individuals at high cardiovascular risk would prevent more cardiovascular events [4, 
5]. This suggests there will be even greater clinical interest in therapies containing two or 
three BP lowering drugs. Currently there is inconsistency across guidelines, with some 
recommending triple combination only after titration to maximal dose of dual combination 
[6], other recommending “add third drug/optimise doses of drugs” [7], while some other 
providing no specific recommendations [1, 2, 8].  Evidence on dose-response relationship of 
individual drugs suggest triple combination even at submaximal doses would be more 
efficacious and tolerable than dual combination at maximal dose [9]. This systematic review 
of RCTs was therefore undertaken to assess the efficacy and safety of triple versus dual 
combination therapy in adults with hypertension. 
Methods 
The protocol for this systematic review was registered at PROSPERO (CRD42014006977) 
before screening for eligible studies to be included in the review.  
Literature search and selection of studies 
Cochrane Central Registry of Controlled Trials, MEDLINE, and Embase were systematically 
searched until April 2018 to identify relevant literature. The search strategy was developed 
using appropriate Medical Subject Headings and free-text terms including key words. Search 




was restricted to RCTs in humans without any language restriction (Supplement Table S1). 
Other electronic sources searched were: Google Scholar, clinicaltrial.gov, World Health 
Organisation - International Clinical Trials Registry Platform, and the websites of Food and 
Drug Administration, European Medicines Agency, and Therapeutic Goods Administration of 
Australia. References of relevant reviews and included trials were also reviewed to identify 
any additional eligible trials.  
Two reviewers (AS & BH) independently reviewed titles and abstracts to exclude clearly 
irrelevant studies. Two reviewers independently screened the full text of potentially eligible 
studies against predefined inclusion criteria. The inclusion criteria were: RCTs of triple vs. dual 
combinations of angiotensin converting enzyme inhibitors [ACEIs], angiotensin receptor 
blockers [ARBs], calcium channel blockers [CCBs], beta-adrenergic blockers [BBs], or 
thiazide/like diuretics [TDs]), in hypertensive (baseline mean SBP≥ 140 or DBP≥ 90 mmHg)  
adults; with a treatment duration of ≥3 weeks, with at least one treatment group randomized 
to triple combination; and at least one treatment group randomized to dual combination; and 
reported data on efficacy (mean change in SBP/DBP from baseline to endpoint). Patients 
enrolled in the included studies could be either receiving antihypertensive drugs or untreated 
at baseline. Studies were excluded if they focused on secondary hypertension or if the use of 
triple or dual combinations was optional (e.g. to reach BP targets). Studies were not excluded 
based on the presence or absence of any disease at baseline. A third reviewer helped to 
resolve any disagreement between the primary reviewers.  
Data extraction and assessment of risk of bias in included studies 
Two reviewers (AS, BH) extracted data independently using a standard, piloted, data 
extraction form including, study and participant characteristics, interventions and outcomes. 




Information relevant for this review but missing from published reports was requested from 
publication authors or study sponsors. Two reviewers (AS & EA) independently assessed risk 
of bias in each included study using Cochrane’s risk of bias assessment tool [10].  
Data management and analysis 
Different drugs and their doses in the triple and dual combinations are a potential source of 
heterogeneity in treatment effects. To explore this, we predicted difference in efficacy 
between triple and dual combination by two published methods and compared them with 
observed difference in efficacy: the method of Law et al. [9], and Therapeutic Intensity Score 
(TIS) [11] (both summarised in Supplementary Table S2).  
Changes in SBP and diastolic blood pressure (DBP) (change in mean from baseline to end of 
treatment) were summarised as a between treatment group difference in mean along with 
95% confidence intervals (CI). Proportion of participants achieving the study’s target BP at the 
end of treatment were summarised as relative risks (RR) with 95% confidence intervals (CI). 
Safety outcomes, defined as withdrawals due to adverse events (WDAEs) and any adverse 
events (AAEs) were summarised as RR (95% CI). Meta-analyses were performed using 
random-effects model with inverse variance weighting. Heterogeneity was detected by Q test 
and quantified by I2 statistics [12]. For trials that involved more than one triple and/or dual 
combination group, to avoid the issue of double counting when multiple comparisons from a 
trial are included in the meta-analysis, the number of patients (and number events for binary 
outcomes) were divided appropriately [12]. To investigate publication bias, a funnel plot [13] 
was produced for the primary outcome of change in BP by combining effects of all triple 
combinations and dual combinations within each trial such that each trial contributed only 




one comparison. Data were prepared in Microsoft Excel and analysed using Comprehensive 
meta-analysis software (V3) [14]. 
Results 
Search results 
The PRISMA flow diagram (Supplement Figure S1) shows the number of studies identified, 
included and excluded. Overall, fourteen trials (40 treatment groups, 11,457 participants) 
were included in this review. 
Characteristics of included trials 
Characteristics of included trials are summarised in Supplement Table S4. All included trials 
were double-blind, parallel group, and multicenter. The proportion of male participants 
ranged from 46% to 83%, and mean age ranged from 53 to 63 years. Overall, baseline mean 
BP was 163/101 mmHg. In all trials BP was measured in-clinic in seated position; at trough in 
ten trials, and four trials did not report the measurement time. All included trials assessed 
triple vs. dual therapy of ACEI/ARB, CCB and TDs. In all but one trial, the dual therapy included 
component drugs of the triple therapy: in one trial [15] the ARB used in triple was valsartan, 
whereas the dual therapy group used losartan. Treatment duration averaged 8 weeks (range 
4 to 10 weeks). 
Five trials [15–19] with a total of 8150 participants had a variable 1 to 4 weeks pre-
randomisation washout of previous BP lowering drugs, and then randomisation to triple or 
dual therapy. Those randomised to triple therapy initially received sub-maximal dose dual 
therapy, in all but one trial [17], before forced-up-titration to triple therapy.  




The other nine trials [20–28] including a total of 3307 participants, had a variable 4 to 8 weeks 
pre-randomisation run-in on sub-maximal dual therapy, in all but one trial [20], before 
randomisation to either triple therapy (with the addition of an extra drug) or continued dual 
therapy.   
Goal BP levels to define BP control were similar across trials: <140 & <90 in seven trials [16–
18, 21–24],  <140 & <90 or (<130 & <80 in those with diabetes and/or kidney disease) in five 
trials [15, 19, 20, 27, 28],  DBP <90 or ≥10 mmHg reduction in DBP from baseline in two trials 
[25, 26].     
Risk of bias in included studies 
Overall, none of the 14 studies had high risk of bias for any of the six domains that were 
assessed. Most trials inadequately reported random sequence generation and allocation 
concealment. These were judged as unclear risk of bias but were considered a reporting 
deficiency given the trial organisation and settings (Supplement Figure S2). The funnel plot 
based on difference in mean SBP reduction did not show asymmetry in dispersion of studies 
(Supplement Figure S3).   
Efficacy 
Figure 1 shows change in SBP from baseline to endpoint by treatment groups across all 
included trials. Overall, in trials with drug-free baseline (mean BP 169/103 mmHg), BP fell on 
average by 36/23 mmHg with triple, compared to 32/19 mmHg with dual combination. In 
trials with active run-in on dual therapy at baseline (mean BP 150/95 mmHg), BP fell on 
average by 14/9 mmHg with triple compared to 9/6 mmHg with continued dual combination. 
Mean BP at endpoint for triple vs. dual therapy was lower for trials with drug free baseline 




(132/81 vs. 138/85 mmHg), compared to trials with dual therapy run-in (137/86 vs. 141/89 
mmHg). 
Overall, triple compared to dual therapy reduced SBP by 5.4 mmHg (95% CI 4.6 to 6.3; I2=60%) 
and DBP by 3.2 mmHg (95% CI 2.6 to 3.8; I2=69%), with similar effects seen in trials with drug-
free baseline compared to those with dual therapy run in (5.2/3.0 vs. 6.0/3.7 mmHg). In 
sensitivity analysis, overall results were similar if each trial provided only one estimate of 
triple vs. dual combination, by pooling all the triple and/or dual groups in the 4 trials [15–17, 
20] with more than two treatment groups: a reduction in SBP by 6.2 mmHg (95% CI 4.9-7.5, 
I2=80%) and DBP by 3.8 mmHg (95% CI 2.9-4.7, I2=85%). Again, similar effects were seen in 
trials with a drug-free baseline compared to those with dual therapy run-in (6.0/3.7 mmHg 
vs. 6.3/3.9 mmHg, respectively). Overall, triple combination achieved goal BP in significantly 
more participants compared to dual combination (58% vs. 45%, RR 1.33 [95% CI 1.25-1.41]).  
For predicting difference in efficacy between triple and dual combination, and hence to 
explain the heterogeneity in effects observed, the Law et al. method was better than TIS 
(Figure 2). The TIS method overestimated the efficacy of high dose dual therapies (incorrectly 
predicting it would be superior to some triple combinations) and also overestimated the 
efficacy of high dose triple therapies. In contrast the Law et al. prediction method matched 
reasonably well with the observed efficacy, correctly predicting that all triple therapies would 
be superior to all dual regimens. However, the observed BP differences tended to be 
moderately smaller than the Law et al.’s predicted BP differences, as seen in Figure 2 and 3.  
The type of drug added to dual combinations did not make a substantial difference to the 
amount of SBP reduction, with the exception that somewhat lower reductions were seen with 
adding hydrochlorothiazide (HCTZ), compared to adding chlorthalidone or amlodipine at 




equivalent standard dose (Supplement Figure S4).  One comparison indicated that sub-
maximal dose triple (olmesartan 20 + amlodipine 5 + hydrochlorothiazide 12.5 mg) was non-
significantly superior to maximum dose dual therapy (olmesartan 40 + amlodipine 10) (0.4/0.4 
mmHg lower BP in triple therapy group).  Two comparisons assessed the efficacy of double 
the dose of one component drug within dual combination vs. dual combination (i.e. 2*A+B 
vs. A+B), and additional BP reduction was 1.5/0.8 mmHg (p>0.5). Twenty-three comparisons 
assessed adding a third drug to dual combinations (i.e. A+B+C vs. A+B, with A and B at same 
doses) and the additional BP reduction was 6.0/3.8 mmHg (p=0.0001). Thus on average 
adding a third drug to dual combination is about four times more efficacious than doubling 
the dose of one of the components of dual combinations. One comparison assessed the 
efficacy of double the dose of both components of dual combination (2*A+2*B vs. A+B) and 
found an additional BP reduction of 2.9/1.6 mmHg (p<0.02) i.e. about half as efficacious as 
adding a third drug.  
Safety 
Overall, from 13 trials (33 comparisons), for triple vs dual therapy, there was no significant 
difference in incidence of WDAEs (3.3% vs. 3.4%, RR 1.24 [95% CI 1.00-1.54], p=0.05, I2=0%), 
and AAEs (33.5% vs. 40%, RR 1.02 [95% CI 0.96-1.07], p=0.55, I2=0%).  
In the meta-analyses by subgroups defined by difference of third drug between triple and vs 
therapy, HCTZ 25 mg had higher incidence of WDAEs (3.4% vs. 2.6%, RR 1.68 [1.08-2.60]), and 
HCTZ 12.5 mg had higher incidence of AAEs (29.6% vs. 26.0%, RR 1.20 [1.03-1.41]) 
(Supplement Figure S5 and S6). Finally, there was no significant difference for WDAEs (3.5% 
vs. 4.5%, RR 0.79 [0.18-3.43]) and AAEs (27.3% vs. 29.2%, RR 0.93 [0.57-1.52]) for sub-maximal 
dose triple compared to maximal dose dual therapy. 





This review demonstrated that triple combination achieves greater BP reduction and control 
compared to dual combination. The absolute benefits were large in terms of improved 
hypertension control. For patients not controlled on sub-maximal dose dual combination, 
adding an extra drug to dual combination could be approximately four times more efficacious 
than doubling the dose of one of the component drugs of dual combination. Efficacy of triple 
combination was similar in patients with drug free baseline and those who were on dual 
therapy. Overall, there was no significant difference in safety outcomes of WDAEs and AAEs, 
however, in subgroup analyses, excess of WDAEs or AAEs seen with triple therapy were 
potentially related to HCTZ when it was one of the component drug along with an ARB and a 
CCB.  
All included trials in this systematic review were double-blind RCTs, and included data from 
more than 11,000 participants. We searched extensively to identify relevant studies, data for 
unpublished studies were sought from the study sponsors, and the review was conducted as 
per the Cochrane Handbook for Systematic Reviews of Interventions [12]. The review also was 
the first to demonstrate that the difference in efficacy of triple and dual combination was well 
predicted by Law et al. [9] but not well predicted by the Therapeutic Intensity Score [11]. 
There are some limitations to consider however. The lack of individual patient data prevented 
more detailed exploration of heterogeneity, and the study of association between predicted 
and observed BP reduction was limited due to small number of available studies. Although 
steps were taken to deal with the issue of double counting when multiple comparisons from 
some trials were included in the meta-analysis, it will not fully account for correlation 
between comparisons. Also, by including multiple comparisons from trials, a random-effects 




model will inflate the heterogeneity between comparisons as it considers these comparisons 
as separate studies. Finally, while heterogeneity in treatment effects was mostly explained by 
regimen potency as explained by Law et al method, further refinements are required.  
A systematic review of 11 studies, including 7563 participants, of triple vs. dual combinations 
was previously published [29]. However, it only assessed efficacy of triple combination of 
ARBs, CCBs and diuretics, and some of the included studies were uncontrolled. This review 
reported 5.8/3.5mmHg reduction in BP with triple combination which is consistent with the 
finding in our study. The results of our review are also consistent with the predicted effects 
of triple vs. dual combinations from the analysis of Law et al. [9].  
Two other trials compared triple combination to placebo or no treatment, but were not 
included in this analysis because not all included patients had hypertension and there was no 
dual combination group included. Wald et al. [30] conducted a crossover trial of a polypill 
(amlodipine 2.5 mg, losartan 25 mg, HCTZ 12.5 mg and simvastatin 40 mg), essentially a triple 
combination of BP lowering drugs each at half standard dose, and reported placebo 
subtracted BP reduction of 17.9/9.8 mmHg, which was closely consistent with the predictions 
from Law et al’s previous review [9]. The TIPS trial [31] tested Polycap (HCTZ 12·5 mg+ 
atenolol 50 mg + ramipril 5 + simvastatin 20 + aspirin 100) versus regimens with no BP 
lowering (simvastatin and/or aspirin) and reported less than expected BP reduction (6.3/4.5 
mmHg). The reasons remain unclear, although the low starting baseline BP of 134/85 mmHg 
and non-adherence to treatment are possible reasons [32]. Finally, a recent trial [33] 
compared low-dose triple therapy with usual care among 700 patients with hypertension, 
either untreated or on monotherapy. This trial demonstrated a large improvement in 




hypertension control rates, with no increase in adverse effects, among those receiving low-
dose triple therapy [34]. 
Currently, there is discrepancy between clinical guidelines on the use of triple combination 
therapy, with some recommending use only in patients not controlled on maximal dose dual 
therapy, others recommending earlier use of triple therapy, and others recommending 
clinicians can choose between the options. This review suggests that guidelines should 
recommend early use of triple therapy, i.e. before using maximal dose dual therapy. However, 
it is important to note that although triple therapy was more efficacious than dual therapy, it 
achieved BP under 140/90 mmHg in only about 60% of the participants, and most patients 
failed to achieve SBP<130 mmHg as recommended for several patient groups in recent 
hypertension guidelines [1, 2]. These data therefore suggest that achieving lower BP goals in 
the range 120-130 mmHg will require early use of three drugs in most patients with 
hypertension. 
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